- Home
- SI vs ABEO Comparison
SI vs ABEO Comparison
Compare SI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | ABEO |
|---|---|---|
| Founded | 2009 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.1M | 280.2M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | SI | ABEO |
|---|---|---|
| Price | $14.60 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $20.80 | $20.00 |
| AVG Volume (30 Days) | 71.1K | ★ 1.2M |
| Earning Date | 05-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $39.59 | $1,024.31 |
| Revenue Next Year | $31.37 | $145.42 |
| P/E Ratio | ★ N/A | $5.46 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $10.92 | $4.00 |
| 52 Week High | $17.23 | $7.54 |
Technical Indicators
Market Signals| Indicator | SI | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 65.20 |
| Support Level | $13.76 | $5.24 |
| Resistance Level | $15.85 | $5.62 |
| Average True Range (ATR) | 0.60 | 0.23 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 55.23 | 85.84 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.